Axa
STML

Axa’s Stemline Therapeutics, Inc. STML Stock Holding History

Axa’s Portfolio STML Stock Details STML Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-582,915
Closed -$6.2M – 1288
2019
Q4 		$6.2M Buy
582,915
+14,571
+3% +$145K 0.03% 569
2019
Q3 		$5.92M Sell
568,344
-850
-0.1% -$11.1K 0.02% 595
2019
Q2 		$8.72M Sell
569,194
-376,373
-40% -$5.44M 0.03% 506
2019
Q1 		$12.2M Buy
945,567
+264,089
+39% +$2.99M 0.05% 408
2018
Q4 		$6.47M Buy
681,478
+229,490
+51% +$2.98M 0.03% 539
2018
Q3 		$7.5M Hold
451,988
– – 0.03% 557
2018
Q2 		$7.25M Sell
451,988
-112,516
-20% -$2.01M 0.03% 547
2018
Q1 		$8.64M Buy
564,504
+14,275
+3% +$223K 0.03% 491
2017
Q4 		$8.58M Sell
550,229
-70,317
-11% -$940K 0.03% 515
2017
Q3 		$6.89M Sell
620,546
-8,659
-1% -$81.4K 0.03% 545
2017
Q2 		$5.79M Buy
629,205
+195,022
+45% +$1.63M 0.03% 571
2017
Q1 		$3.71M Buy
+434,183
New +$3.96M 0.02% 652

Other funds holding STML

EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Manulife (Manufacturers Life Insurance)
Manulife (Manufacturers Life Insurance) Canada, Ontario, Canada $116B AUM 26.37% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
CC
Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return

Axa's STML Position: Q1 2020 in Review

Axa sold out of Stemline Therapeutics, Inc. (STML) in Q1 2020, closing a stake of 582,915 shares — an estimated $6.2M sold.

Axa first reported a position in STML in Q1 2017 and held it in 12 quarters. The position peaked at $12.2M in Q1 2019. 94 funds tracked by Wall St. Rank hold STML as of Q1 2020.

  • Axa reported no remaining Stemline Therapeutics, Inc. position as of Q1 2020 after selling out during the quarter.
  • Axa sold 582,915 Stemline Therapeutics, Inc. shares in Q1 2020, an estimated $6.2M.
  • Axa first reported a position in Stemline Therapeutics, Inc. in Q1 2017 and held it in 12 quarters.
  • Axa's Stemline Therapeutics, Inc. position peaked at $12.2M in Q1 2019.
  • 94 funds tracked by Wall St. Rank held Stemline Therapeutics, Inc. as of Q1 2020.

Based on Axa's 13F filing for Q1 2020, filed 15 May 2020.